Left ventricular hypertrophy in renal disease: Beyond preload and afterload

Kidney International

Volumn 75, Issue 8, 2009, Pages 771-773

  Ritz, Eberhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MARINOBUFAGENIN; RAPAMYCIN;

CHRONIC KIDNEY DISEASE; CONCENTRIC MUSCLE CONTRACTION; ECCENTRIC MUSCLE CONTRACTION; EXPERIMENTAL MODEL; FIBROGENESIS; HEART AFTERLOAD; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PRELOAD; HYPERTENSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; UREMIA;

EID: 63849328147     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.35     Document Type: Note

References (12)

1. Rambausek M , Ritz E , Mall G et al. Myocardial hypertrophy in rats with renal insufficiency . Kidney Int 1985 ; 28 : 775 -782.
2. Frey N , Katus HA , O lson EN et al. Hypertrophy of the heart: a new therapeutic target? Circulation 2004 ; 109 : 1580 -1589.
3. Proud CG . Ras PI3-kinase and mTOR signaling in cardiac hypertrophy . Cardiovasc Res 2004 ; 63 : 403 -413 .
4. Scheuer J , N ivatpumin T , Yipintsoi T Effects of moderate uremia on cardiac contractile responses . Proc Soc Exp Biol Med 1975 ; 150 : 471-474 .
5. K ennedy DJ , Vetteth S , Periyasamy SM et al. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy . Hypertension 2006 ; 47 : 488 -495 .
6. Siedlecki AM , Jin X , Muslin AJ . Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure . Kidney Int 2009 ; 75 : 800-808 .
7. Zeisberg EM , Tarnavski O , Zeisberg M et al. Endothelial-to- mesenchymal transition contributes to cardiac fibrosis . Nat Med 2007 ; 13 : 952-961 .
8. Shioi T , McM ullen JR , Tarnavski O et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice . Circulation 2003 ; 107 : 1664-1670 .
9. Crespo-Leiro MG , Hermida-Prieto M . Sirolimus treatment of left ventricular hypertrophy: who, and when? Eur Heart J 2008 ; 29 : 2703-2704 .
10. Lee CH , Inoki K , G uan KL . mTOR pathway as a target in tissue hypertrophy . Annu Rev Pharmacol Toxicol 2007 ; 47 : 443-467 .
11. van Rooij E , Marshall WS , O lson EN . Toward microRNA-based therapeutics for heart disease: the sense in antisense . Circ Res 2008 ; 103 : 919-928 .
12. Back J, Olson EN C.ontrol of ca rdiac growth by histone acetylation/deacetylation . Circ Res 2006 ; 98 : 15-24 .